Serum immunoglobulin concentrations of JAK3-deficient patients after transplantation
. | . | . | . | Serum isotype concentration* . | . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Time of study† . | % donor B cells‡ . | IVIG . | IgG . | IgA . | IgM . | ||
| Patient no. | ||||||||
| 1 | 3 | 100 | No | 1368 | 139 | 277 | ||
| 2 | 18 | 0 | No | 389 | 17 | 127 | ||
| 3 | 12 | 6 | Yes | NA | 82 | 374 | ||
| 4 | 4 | 1 | Yes | NA | 42 | 57 | ||
| 5 | 10 | 3 | No | 1020 | 248 | 163 | ||
| 6 | 8 | 0 | Yes | NA | 0 | 83 | ||
| 8 | 10 | 1 | Yes | NA | 0 | 104 | ||
| 9 | 9 | 0 | Yes | NA | 79 | 69 | ||
| 10 | 7 | 1 | Yes | NA | 55 | 82 | ||
| Mean ± SD | 9 ± 4 | NA | NA | 744 ± 386 | 73 ± 79 | 148 ± 108 | ||
| Normal§ | NA | NA | NA | 535-1432 | 102-644 | 29-120 | ||
. | . | . | . | Serum isotype concentration* . | . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Time of study† . | % donor B cells‡ . | IVIG . | IgG . | IgA . | IgM . | ||
| Patient no. | ||||||||
| 1 | 3 | 100 | No | 1368 | 139 | 277 | ||
| 2 | 18 | 0 | No | 389 | 17 | 127 | ||
| 3 | 12 | 6 | Yes | NA | 82 | 374 | ||
| 4 | 4 | 1 | Yes | NA | 42 | 57 | ||
| 5 | 10 | 3 | No | 1020 | 248 | 163 | ||
| 6 | 8 | 0 | Yes | NA | 0 | 83 | ||
| 8 | 10 | 1 | Yes | NA | 0 | 104 | ||
| 9 | 9 | 0 | Yes | NA | 79 | 69 | ||
| 10 | 7 | 1 | Yes | NA | 55 | 82 | ||
| Mean ± SD | 9 ± 4 | NA | NA | 744 ± 386 | 73 ± 79 | 148 ± 108 | ||
| Normal§ | NA | NA | NA | 535-1432 | 102-644 | 29-120 | ||
NA indicates not applicable.
Values are milligrams per deciliter. IgG values of patients on IVIG therapy are not shown
Number of years after most recent transplantation when experiments were performed (median = 9 years).
As determined by restriction fragment length polymorphism (RFLP) or fluorescence in situ hybridization (FISH) analysis of patient EBV-transformed B-cell lines established after transplantation.
Normal values are 95% confidence intervals for age 11 years (median current age for the 9 surviving patients).